罗氏从5.7亿美元从宜联生物引进B7H3 ADC，加码SCLC布局

Minhua笔记01-10

1月8日，罗氏（Roche）宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议，获得后者靶向B7H3的ADC tambotatug pelitecan（YL201）中国以外地区的全球独家权益。这一交易是罗氏2025年以来第三笔ADC重磅合作，也是与宜联生物双方不到两年内第二次携手。罗氏加倍投入小细胞肺癌（SCLC）的抗体药物偶联物（ADC）研发，再次与现有合作伙伴宜联生物（MediLink ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602960582?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-10 16:41","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2602960582","market":"hk","top_or_hot":-1,"title":"罗氏从5.7亿美元从宜联生物引进B7H3 ADC，加码SCLC布局","media":"Minhua笔记","content":"<div>\n<p>1月8日，罗氏（Roche）宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议，获得后者靶向B7H3的ADC tambotatug pelitecan（YL201）中国以外地区的全球独家权益。这一交易是罗氏2025年以来第三笔ADC重磅合作，也是与宜联生物双方不到两年内第二次携手。罗氏加倍投入小细胞肺癌（SCLC）的抗体药物偶联物（ADC）研发，再次与现有合作伙伴宜联生物（MediLink ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>罗氏从5.7亿美元从宜联生物引进B7H3 ADC，加码SCLC布局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n罗氏从5.7亿美元从宜联生物引进B7H3 ADC，加码SCLC布局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 16:41 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b><strong>Minhua笔记</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1月8日，罗氏（Roche）宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议，获得后者靶向B7H3的ADC tambotatug pelitecan（YL201）中国以外地区的全球独家权益。这一交易是罗氏2025年以来第三笔ADC重磅合作，也是与宜联生物双方不到两年内第二次携手。罗氏加倍投入小细胞肺癌（SCLC）的抗体药物偶联物（ADC）研发，再次与现有合作伙伴宜联生物（MediLink ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b","article_id":"2602960582","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110164641a4b35e86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602960582","pubTimestamp":1768034502,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"1月8日，罗氏宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议，获得后者靶向B7H3的ADC tambotatug pelitecan中国以外地区的全球独家权益。双方于2024年初首次合作，达成一项价值近10亿美元的协议，共同开发宜联生物的ADC药物YL211，该药物靶向c-Met，用于治疗实体瘤。据宜联生物称，初步数据显示，该药物在SCLC二线治疗中展现出令人鼓舞的客观缓解率和生存获益。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1589":"北水核心资产","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1161":"生物科技","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","MRK":"默沙东","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1583":"高瓴概念","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"Roche introduced B7H3 ADC from Yilian Biotech for US $570 million, increasing its SCLC layout","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":0.9,"MRK":0.9},"content_text":"1月8日，罗氏（Roche）宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议，获得后者靶向B7H3的ADC tambotatug pelitecan（YL201）中国以外地区的全球独家权益。这一交易是罗氏2025年以来第三笔ADC重磅合作，也是与宜联生物双方不到两年内第二次携手。罗氏加倍投入小细胞肺癌（SCLC）的抗体药物偶联物（ADC）研发，再次与现有合作伙伴宜联生物（MediLink Therapeutics）达成协议，共同开发靶向B7H3的ADC候选药物tambotatug pelitecan（YL201）。该协议于1月8日宣布，包括5.7亿美元的首付款和近期付款，宜联生物还有资格获得其他未披露的研发、监管和商业里程碑付款，以及中国以外地区的分级销售分成。双方于2024年初首次合作，达成一项价值近10亿美元的协议，共同开发宜联生物的ADC药物YL211，该药物靶向c-Met，用于治疗实体瘤。关于tambotatug pelitecan的新合作协议涵盖多种实体瘤，该药物目前已在中国进入SCLC和鼻咽癌的III期临床试验。据宜联生物称，初步数据显示，该药物在SCLC二线治疗中展现出令人鼓舞的客观缓解率和生存获益。在SCLC领域，罗氏去年与信达生物签署了一项价值可能超过10亿美元的协议，共同开发和商业化靶向DLL3的ADCIBI3009。“我们与宜联生物深化合作……体现了罗氏致力于利用前沿创新……满足患者未被满足的需求，尤其是在肿瘤和肺癌领域，这是我们的战略重点之一，”罗氏的全球企业业务发展负责人Boris Zaïtra表示。根据双方达成的协议，罗氏将获得除中国外在全球范围内开发、生产和销售 tambotatug pelitecan 的独家许可。宜联生物联合创始人兼联合首席执行官蔡家强表示，与罗氏的合作是该药物全球开发进程中的“变革性一步”。“这项协议为我们创新的 TMALIN 平台的核心资产——tambotatug pelitecan提供了推进全球化所需的资源与渠道，使其有望成为一种新的治疗选择。”尽管B7H3靶点引起了药物研发人员的日益关注，但上个月，第一三共暂停了其与默沙东合作开发的ADC ifinatamab deruxtecan (I-DXd) 治疗复发性SCLC患者的III期IDeate-Lung02研究的招募工作，这给该靶点带来了挫折。暂停的原因是多名患者死于间质性肺病。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602960582","isCrawlerRequest":true}